image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 5.2
-2.26 %
$ 660 M
Market Cap
-520.0
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ORGO stock under the worst case scenario is HIDDEN Compared to the current market price of 5.2 USD, Organogenesis Holdings Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ORGO stock under the base case scenario is HIDDEN Compared to the current market price of 5.2 USD, Organogenesis Holdings Inc. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one ORGO stock under the best case scenario is HIDDEN Compared to the current market price of 5.2 USD, Organogenesis Holdings Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ORGO

image
$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0$4.5$4.5$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.515 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
482 M REVENUE
11.29%
-1.28 M OPERATING INCOME
-10.24%
861 K NET INCOME
-82.59%
14.2 M OPERATING CASH FLOW
-54.04%
-10 M INVESTING CASH FLOW
58.82%
27.6 M FINANCING CASH FLOW
602.03%
127 M REVENUE
9.97%
10.2 M OPERATING INCOME
63.71%
7.67 M NET INCOME
-37.77%
10.9 M OPERATING CASH FLOW
25.78%
-3.36 M INVESTING CASH FLOW
-30.83%
33.6 M FINANCING CASH FLOW
2106.50%
Balance Sheet Organogenesis Holdings Inc.
image
Current Assets 286 M
Cash & Short-Term Investments 136 M
Receivables 110 M
Other Current Assets 40.5 M
Non-Current Assets 212 M
Long-Term Investments 0
PP&E 126 M
Other Non-Current Assets 85.7 M
27.23 %22.07 %8.14 %25.35 %17.21 %Total Assets$497.9m
Current Liabilities 77.5 M
Accounts Payable 28.9 M
Short-Term Debt 9.11 M
Other Current Liabilities 39.5 M
Non-Current Liabilities 35.1 M
Long-Term Debt 0
Other Non-Current Liabilities 35.1 M
25.68 %8.10 %35.05 %31.17 %Total Liabilities$112.6m
EFFICIENCY
Earnings Waterfall Organogenesis Holdings Inc.
image
Revenue 482 M
Cost Of Revenue 116 M
Gross Profit 366 M
Operating Expenses 368 M
Operating Income -1.28 M
Other Expenses -2.14 M
Net Income 861 K
500m500m450m450m400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)482m(116m)366m(368m)(1m)2m861kRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
75.99% GROSS MARGIN
75.99%
-0.27% OPERATING MARGIN
-0.27%
0.18% NET MARGIN
0.18%
0.22% ROE
0.22%
0.17% ROA
0.17%
0.09% ROIC
0.09%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Organogenesis Holdings Inc.
image
40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 861 K
Depreciation & Amortization 17 M
Capital Expenditures -10 M
Stock-Based Compensation 10.6 M
Change in Working Capital 0
Others -3.54 M
Free Cash Flow 4.18 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Organogenesis Holdings Inc.
image
Wall Street analysts predict an average 1-year price target for ORGO of $5.5 , with forecasts ranging from a low of $5 to a high of $6 .
ORGO Lowest Price Target Wall Street Target
5 USD -3.85%
ORGO Average Price Target Wall Street Target
5.5 USD 5.77%
ORGO Highest Price Target Wall Street Target
6 USD 15.38%
Price
Max Price Target
Min Price Target
Average Price Target
77666655554444333322Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Organogenesis Holdings Inc.
image
Sold
0-3 MONTHS
128 K USD 1
3-6 MONTHS
1.36 M USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Burn Care Market worth $3.35 billion by 2030 with 5.6% CAGR | MarketsandMarkets™ DELRAY BEACH, Fla., May 2, 2025 /PRNewswire/ -- The global Burn Care Market, valued at US$2.46 billion in 2024, is forecasted to grow at a robust CAGR of 5.6%, reaching US$2.55 billion in 2025 and an impressive US$3.35 billion by 2030. This market is experiencing consistent growth due to several key factors. The number of burn injuries is rising due to factors such as industrial accidents, domestic fires, and other hazards. Furthermore, advancements in treatment technologies and increased awareness and education about burn care contribute to this trend. Additionally, supportive government initiatives play a significant role in market development. The demand for effective burn treatments is rising as the global population ages. Older individuals are more susceptible to slow-healing wounds and burn complications, which, in turn, increases the need for advanced burn care products. Moreover, technological advancements in burn treatment—including innovative burn dressings, biologics, and advanced burn wound assessment devices—enhance treatment efficiency and effectiveness. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=247121470 Browse in-depth TOC on "Burn Care Market" 345 - Tables 45 - Figures 302 - Pages By Based on products, the burn care market is categorized into five segments: advanced burn dressings, burn wound therapy devices, biologics, traditional burn care products, and other burn care products. Among these, the biologics segment is expected to register the highest CAGR during the forecast period. This growth is driven by the rising demand for advanced and effective treatment options for deep and complex burns. Biologics provide targeted healing, minimize long-term complications, and promote tissue regeneration, making them particularly suitable for treating severe burns. The increasing acceptance of these products among healthcare professionals and ongoing innovations in regenerative medicine are contributing to the strong and sustained growth of the biologics segment. By Based on burn degree, the burn care market is divided into first-degree burns (minor burns), second-degree burns (partial-thickness burns), and third-degree burns (full-thickness burns). Of these, the second-degree burns segment accounted for the largest market share of the burn care market in 2024. This is largely because partial-thickness burns occur more frequently. These burns tend to destroy the epidermis and dermis; as such, they require the application of advanced burn care products, which drives consistent demand in this segment. By geography, the market for burn care is divided into five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the burn care market in 2024 with the largest market share. This is primarily because countries like the US and Canada have well-developed healthcare facilities, supporting widespread access to advanced burn care products and treatments. The region also experiences a high rate of burn injuries. The availability of key players and constant investment in research & development further consolidate North America's position in the burn care market. Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=247121470 The major players operating in this market are Smith+Nephew (UK), Mölnlycke Health Care AB (Sweden), Cardinal Health Inc. (US), Integra LifeSciences Holdings Corporation (US), ConvaTec Group Plc (UK), Coloplast Group (Denmark), Solventum Corporation (US), Essity Aktiebolag (Sweden), PAUL HARTMANN AG (Germany), and Organogenesis Holdings Inc. (US). SMITH+NEPHEW (UK) Smith+Nephew is distinguished by its advanced wound care solutions and robust research and development capabilities, enabling it to provide effective burn care products. Mölnlycke Health Care AB has solidified its market position through strategic partnerships. Cardinal Health Inc. utilizes its extensive distribution network and diverse product line to reach a wide range of healthcare facilities, thereby increasing its share in the burn care market. Integra LifeSciences Holdings Corporation is recognized for its broad range of biologics that offer crucial support for severe burns. ConvaTec Group Plc has strengthened its market presence through global expansion and strategic acquisitions. MOLNLYCKE HEALTH CARE AB (SWEDEN): Mölnlycke Health Care AB also boasts a comprehensive product portfolio in the advanced wound care market. The company's leading position in this sector is largely due to its robust global sales and distribution network, which allows it to effectively market its products in various countries. Mölnlycke primarily utilizes inorganic strategies, such as partnerships, to maintain its market position. For example, in May 2024, the company formed a new partnership with the Phoenix Society, a burn survivor organization in the US. Through this collaboration, Mölnlycke will support the Phoenix Society's initiatives with its extensive range of burn care solutions For more information, Inquire Now! Related Reports: Wound Care Biologics Market Advanced Wound Care Market Point of Care Diagnostics Market Wound Care Market Point of Care Molecular Diagnostics Market Get access to the latest updates on Burn Care Companies and Burn Care Market Size About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress Ave.Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: [email protected]Visit Our Website: https://www.marketsandmarkets.com/ Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg https://www.prnewswire.com - 2 weeks ago
Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness Organogenesis recommends CMS also implement an integrated coverage and payment policy Organogenesis recommends CMS also implement an integrated coverage and payment policy globenewswire.com - 1 month ago
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025 CANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, May 8th. globenewswire.com - 1 month ago
Organogenesis Holdings Inc. (ORGO) Q4 2024 Earnings Call Transcript Organogenesis Holdings Inc. (NASDAQ:ORGO ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Gary S. Gillheeney, Sr. – President and Chief Executive Officer Dave Francisco – Chief Financial Officer Conference Call Participants Brooks O'Neil – Lake Street Capital Markets Ross Osborn – Cantor Fitzgerald Ryan Zimmerman – BTIG Operator Please standby. seekingalpha.com - 2 months ago
Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results CANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2024. globenewswire.com - 2 months ago
Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025 CANTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2024 financial results will be reported after the market closes on Thursday, February 27th. globenewswire.com - 3 months ago
Organogenesis Expands Manufacturing Capacity to Support Future Growth CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. globenewswire.com - 5 months ago
Organogenesis Commends Final LCDs Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination Organogenesis Pleased to Lead Collaborative Effort to Support Data-Driven Policy on Local Coverage Determination globenewswire.com - 6 months ago
Organogenesis Holdings, Inc. (ORGO) Q3 2024 Earnings Call Transcript Organogenesis Holdings, Inc. (NASDAQ:ORGO ) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ET Company Participants Gary Gillheeney - President, Chief Executive Officer & Chair Dave Francisco - Chief Financial Officer Conference Call Participants Ross Osborne - Cantor Fitzgerald Ryan Zimmerman - BTIG Operator Please stand by. Welcome ladies and gentlemen to the Third Quarter of Fiscal Year 2024 Earnings Conference Call for Organogenesis Holdings Inc. At this time, all participants are placed in listen-only mode. seekingalpha.com - 6 months ago
Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock Net proceeds to fund the Company's strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases Net proceeds to fund the Company's strategic growth initiatives, enhance balance sheet flexibility, and finance privately negotiated stock repurchases globenewswire.com - 6 months ago
Organogenesis Reports Positive Interim Analysis of Second Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis CANTON, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the favorable outcome of the interim analysis of its second Phase 3 randomized control trial of ReNu, a cryopreserved amniotic suspension allograft (ASA), for the management of symptoms associated with knee osteoarthritis (OA). globenewswire.com - 6 months ago
Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2024 Financial Results on November 12, 2024 CANTON, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2024 financial results will be reported after the market closes on Tuesday, November 12th. globenewswire.com - 7 months ago
8. Profile Summary

Organogenesis Holdings Inc. ORGO

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 660 M
Dividend Yield 0.43%
Description Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Contact 85 Dan Road, Canton, MA, 02021 https://organogenesis.com
IPO Date Jan. 5, 2017
Employees 869
Officers Mr. Robert Cavorsi Vice President of Strategy Mr. David C. Francisco Chief Financial Officer Mr. Patrick Bilbo Chief Operating Officer Mr. Brian Grow Chief Commercial Officer Mr. William R. Kolb CPA Secretary Ms. Lori H. Freedman B.A., Esq., J.D. Chief Administrative & Legal Officer Mr. Gary S. Gillheeney Sr. President, Chief Executive Officer, Chair of the Board